Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
237.5B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
96.8B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
76B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
63.8B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
28.9B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.6B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.2B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.8B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.5B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.2B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Dr. Lal PathLabs Ltd
Glance View
Dr. Lal PathLabs Ltd. traces its origins back to 1949 when Dr. S.K. Lal, a committed professional with a vision for transforming patient care in India, laid its foundation. With a single laboratory in Delhi, the firm embarked on a journey to make diagnostic services accessible, accurate, and affordable for millions. Over the years, the company's dedication to eking out a niche in the healthcare sector was epitomized by its expansive network that bridges urban and rural India. As of today, it boasts a robust footprint with thousands of patient service centers and diagnostic facilities, enabling them to deliver high-quality pathology services across the length and breadth of the country. This network is instrumental in addressing the diagnostic needs of individuals, bringing specialized tests and healthcare packages within arm's reach of the populace, thus weaving healthcare into the fabric of everyday life. Financially, Dr. Lal PathLabs Ltd. thrives on a well-oiled operational model that deftly balances reach, scalability, and innovation. The company's revenue streams are predominantly anchored in routine and specialized pathology tests, ranging from basic blood tests to complex genetic analyses. By deploying state-of-the-art technology and adhering to high standards of quality control, the firm ensures precision, which instills trust and sustains its business growth. Additionally, strategic collaborations with hospitals, corporate health programs, and wellness initiatives further bolster its financial health. This integrative approach, coupled with a commitment to swallowing costs through operational efficiencies, allows Dr. Lal PathLabs to maintain competitive pricing strategies, thus ensuring sustainable profitability while continuing to innovate in the face of an ever-evolving healthcare landscape.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Dr. Lal PathLabs Ltd is 80.6%, which is above its 3-year median of 79.4%.
Over the last 3 years, Dr. Lal PathLabs Ltd’s Gross Margin has increased from 77.4% to 80.6%. During this period, it reached a low of 76.5% on Mar 31, 2023 and a high of 80.6% on Jun 30, 2025.